在肥胖和性腺功能减退的老年男性中,睾酮联合强化生活方式干预的代谢效应
该研究为随机双盲安慰剂对照试验的二次分析,纳入83例年龄≥65岁、肥胖且持续低睾酮的衰弱男性,比较生活方式干预联合睾酮或安慰剂6个月的效果。结果显示两组HbA1c下降相似,睾酮未增强生活方式干预的代谢获益,反而消除了其对高密度脂蛋白胆固醇和脂联素的提升作用。
要点
- 在肥胖和性腺功能减退的老年男性中,生活方式干预联合睾酮6个月未进一步改善心血管代谢指标。
- 睾酮联合治疗消除了生活方式干预对高密度脂蛋白胆固醇和脂联素的提升效应。
- 两组HbA1c下降相似,睾酮未增强生活方式干预的降糖效果。
核心结论
- 在肥胖和性腺功能减退的老年男性中,生活方式干预联合睾酮6个月未进一步改善心血管代谢指标,并可能削弱生活方式干预的部分代谢获益。
研究设计与样本
- 随机双盲安慰剂对照试验的二次分析,纳入83例年龄≥65岁、体重指数≥30 kg/m2、持续低血清睾酮(<10.4 nmol/L)且伴衰弱的老年男性,来自退伍军人事务医疗中心。
主要发现
- HbA1c在生活方式干预联合睾酮组和生活方式干预联合安慰剂组下降幅度相似(-0.5 ± 0.1% vs -0.6 ± 0.1%,P = 0.35)。
- 高密度脂蛋白胆固醇变化:生活方式干预联合安慰剂组为5.4 ± 1.0 mg/dL,生活方式干预联合睾酮组为0.2 ± 1.1 mg/dL(P = .01)。
- 脂联素变化:生活方式干预联合睾酮组为-408 ± 489 ng/mL,生活方式干预联合安慰剂组为1832 ± 468 ng/mL(P = .02)。
- 睾酮对次要结局未显示与生活方式干预的协同效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether testosterone replacement therapy (TRT) conveys additional cardiometabolic benefit to an intensive lifestyle therapy (LT) in older men with obesity and hypogonadism remains unclear. OBJECTIVE: To determine whether TRT augments the effect of LT on metabolic outcomes in older men with obesity and hypogonadism. DESIGN: Secondary analysis of a randomized, double-blind, placebo-controlled trial. SETTING: Veterans Affairs Medical Center. PARTICIPANTS: Eighty-three older (age ≥ 65 years) men with obesity (body mass index ≥ 30 kg/m2) and persistently low Am testosterone (< 10.4 nmol/L) associated with frailty. INTERVENTIONS: LT (weight management and exercise training) plus either testosterone (LT + TRT) or placebo (LT + Pbo) for 6 months. OUTCOME MEASURES: The primary outcome was change in glycated hemoglobin (HbA1c). Secondary outcomes included changes in other glucometabolic and lipid profile components, liver enzymes, inflammatory markers, and adipokines; subcutaneous, visceral, intramuscular, and hepatic fat; blood pressure; and metabolic syndrome score. RESULTS: HbA1c decreased similarly in LT + TRT and LT + Pbo groups (-0.5 ± 0.1 vs -0.6 ± 0.1%, respectively; P = 0.35). While TRT showed no synergistic effect with LT on ameliorating secondary outcomes, it eliminated the augmentative effect of LT on high-density lipoprotein cholesterol concentration (5.4 ± 1.0 mg/dL in the LT + Pbo group vs 0.2 ± 1.1 mg/dL in the LT + TRT group, P = .01) and adiponectin levels (-408 ± 489 ng/mL in LT + TRT group vs 1832 ± 468 ng/mL in LT + Pbo group, P = .02). CONCLUSION: In older men with obesity and hypogonadism, adding TRT for 6 months to LT does not result in further improved cardiometabolic profiles and could potentially blunt some of the metabolic benefits induced by LT.
引用
- Gonzalez-Gil AM, Barnouin Y, Celli A, et al. Metabolic Effects of Testosterone Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism. J Clin Endocrinol Metab. 2025. PMID: 38606934. doi:10.1210/clinem/dgae249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。